# Xeris Biopharma Holdings, Inc. (XERS)

> Source: Nexqual · https://nexqual.com/XERS · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Xeris Biopharma Holdings, Inc. (XERS), nexqual.com/XERS" · informational, not investment advice.

**Price:** USD 10.75 (+1.03% on the day) · last close of Oct 29, 2026; US market after hours, not a live price. Prev close 10.64 · day 10.71–10.94 · 52w 5.25–11.42 · market cap $1.96B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $335M, net income -$17.2M (-5.1% margin) (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (7 analysts), mean target USD 12.86 (range 8–18).
- Total return with dividends: 1Y +10.7% vs S&P 500 +14.4%; 5Y +478.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD 0.03, revenue estimate $102M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $49.6M | $110M | $164M | $203M | $292M | $335M |
| Operating income | -$115M | -$81.9M | -$44.0M | -$33.6M | $24.9M | $36.6M |
| Net income | -$123M | -$94.7M | -$62.3M | -$54.8M | $554K | -$17.2M |
| EPS (diluted) | -$1.55 | -$0.70 | -$0.45 | -$0.37 | $0.00 | — |
| Free cash flow | -$96.6M | — | — | — | — | — |
| Operating margin | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% | 10.9% |
| Net margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% | -5.1% |
| Revenue growth | +142.7% | +122.3% | +48.7% | +23.9% | +43.7% | — |
| Cash + short-term investments | $102M | $122M | $72.5M | $71.6M | — | — |
| Total debt | $88.1M | $187M | $191M | $232M | $220M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 5.8x · Earnings yield -0.88%
P/E at fiscal year-ends: Dec 2025 2447.7x.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 7 analysts; mean target USD 12.86 (low 8, high 18).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | Barclays | Target raised | Overweight | $12 → $14 |
| 2026-09-10 | Leerink Partners | Target raised | Outperform | $12 → $16 |
| 2026-08-20 | Barclays | Target raised | Overweight | $9 → $12 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +10.7% | +478.0% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +10.8% | +41.9% |
| Volatility (annualized) | 54.7% | 65.5% |
| Max drawdown | -46.6% (Nov 2025→Mar 2026) | -64.2% (Dec 2021→Jan 2023) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 41.84 +1.85% · BHC (Bausch Health Companies Inc.) USD 8.91 +28.76% · RGC (Regencell Bioscience Holdings L) USD 6.86 -5.64% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 28.68 +2.17% · LQDA (Liquidia Corporation) USD 44.99 -1.60% · INDV (Indivior Pharmaceuticals, Inc.) USD 35.25 +1.38%

## More
Full page: https://nexqual.com/XERS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-06)

- "We received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new Keveyis patent expected to extend intellectual property protection through at least 2039, reinforcing our long-term commitment to the primary periodic paralysis community."
- "Once granted, it is expected to provide intellectual property protection for Keveyis through at least 2039. • Notice of Allowance for New Patent Covering XP-8121: On July 28, 2026, the USPTO granted Xeris U.S."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.03 | $0.04 | -37.2% | $101.7M | 3 |
| Next quarter (ends 2026-12-31) | $0.03 | $0.08 | -58.3% | $111.0M | 3 |
| Current fiscal year (ends 2026-12-31) | $-0.09 | $0.14 | −$0.23 | $387.9M | 3 |
| Next fiscal year (ends 2027-12-31) | $0.20 | $0.40 | -50.2% | $480.0M | 3 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.00 | $0.00 | In line | — |
| — | Quarter ended Mar 31, 2026 | $0.01 | $0.00 | Beat +$0.01 | — |
| — | Quarter ended Dec 31, 2025 | $0.06 | $0.05 | Beat +20.0% | — |
| — | Quarter ended Sep 30, 2025 | $0.00 | $0.00 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-14 | 8-K | Other material event — “On October 13, 2026, Xeris Biopharma Holdings, Inc. (the "Company"), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for the District of New Jersey against defendants (i) Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, and Lemed Specialty Pharmacy Arizona, LLC; and (ii) Rising Pharma Holdings, Inc. and Rising Pharma Specialties Pvt. Ltd. in two separate actions.…” | https://www.sec.gov/Archives/edgar/data/1867096/000186709626000091/0001867096-26-000091-index.htm |
| 2026-09-09 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/0001867096-26-000077-index.htm |
| 2026-08-06 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1867096/000186709626000065/0001867096-26-000065-index.htm |
| 2026-08-06 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/0001867096-26-000063-index.htm |
| 2026-07-31 | Schedule 13G | Vanguard Capital Management: 5.0% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1867096/000210011926001430/0002100119-26-001430-index.htm |
| 2026-07-17 | 8-K | Unregistered sale of shares; Other material event — “On July 15, 2026, Xeris Biopharma Holdings, Inc. (the "Company") completed the privately negotiated exchange transactions previously disclosed in its Current Report on Form 8-K filed on June 11, 2026 (collectively, the "Exchange Transactions") with certain holders (the "Exchanging Noteholders") of its 8.00% Convertible Senior Notes due 2028 (the "2028 Notes"). In the Exchange Transactions, the Exchanging Noteholders exchanged approximately $23 million in aggregate principal amount of the 2028 Notes for an…” | https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/0001867096-26-000055-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.